Amarna Therapeutics B.V.

6 articles about Amarna Therapeutics B.V.

• 

  BioSpace Movers & Shakers, Nov. 6

  11/6/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Global Roundup, Oct. 17

  10/17/2019

  Companies from across the globe provide business and pipeline updates.

• Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board

  10/16/2019

  Amarna Therapeutics, a privately held biotechnology company developing a next-generation SV40-based gene delivery vector platform named SVac that promises to transform gene-replacement and immunotherapy across many disease areas, today announced that it has raised €10 million.

• Amarna Therapeutics B.V. Teaming Up with Austrian CBmed In The Development Of Immunotherapies

  6/29/2015

• Amarna Therapeutics B.V. And TNO Announce SVac Research And Development Partnership

  6/10/2009